H.C. Wainwright downgraded Galectin Therapeutics (GALT) to Neutral from Buy.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GALT:
- Largest borrow rate increases among liquid names
- Biotech Alert: Searches spiking for these stocks today
- Galectin Therapeutics announces results from NAVIGATE trial on belapectin
- Galectin Therapeutics presents three abstracts at AASLD 2024 Liver Meeting
- Galectin Therapeutics Reports Increased Q3 Losses